Candel Plans to Submit Biologics License Application
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy CADL?
Source: stocktwits
- Clinical Trial Success: Candel's Phase 3 trial met its primary endpoint, demonstrating that 745 patients receiving the therapy had longer disease-free survival compared to those on standard care, indicating the efficacy of its prostate cancer treatment and potentially accelerating FDA approval.
- Biologics License Application Plan: The company plans to submit a Biologics License Application (BLA) to the U.S. FDA by Q4 2026, marking a critical step towards market entry for its prostate cancer therapy, which is expected to significantly enhance its position in the biopharmaceutical sector.
- Positive Market Reaction: Candel's shares rose 3% in pre-market trading on Friday, reflecting investor optimism ahead of pivotal data presentation at the American Urological Association Annual Meeting, particularly regarding follow-up data that has garnered market attention.
- Improved Financial Performance: Candel reported a Q1 loss of $0.14 per share, better than the expected loss of $0.33, indicating improvements in financial management and operational efficiency, which may boost investor confidence and drive further stock price increases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CADL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CADL
Wall Street analysts forecast CADL stock price to rise
6 Analyst Rating
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 8.910
Low
7.00
Averages
18.33
High
25.00
Current: 8.910
Low
7.00
Averages
18.33
High
25.00
About CADL
Candel Therapeutics, Inc. is a BLA-ready clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic antitumor immune response to help patients fight cancer. CAN-2409 is the lead product candidate from the adenovirus platform. CAN-3110 is the lead product candidate from the herpes simplex virus (HSV) platform and is in an ongoing phase Ib clinical trial in recurrent high-grade glioma. Its enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. CAN-2409, Its advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s specific tumor and induce an individualized, systemic immune response against the tumor.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Candel Plans to Submit Biologics License Application
- Clinical Trial Success: Candel's Phase 3 trial met its primary endpoint, demonstrating that 745 patients receiving the therapy had longer disease-free survival compared to those on standard care, indicating the efficacy of its prostate cancer treatment and potentially accelerating FDA approval.
- Biologics License Application Plan: The company plans to submit a Biologics License Application (BLA) to the U.S. FDA by Q4 2026, marking a critical step towards market entry for its prostate cancer therapy, which is expected to significantly enhance its position in the biopharmaceutical sector.
- Positive Market Reaction: Candel's shares rose 3% in pre-market trading on Friday, reflecting investor optimism ahead of pivotal data presentation at the American Urological Association Annual Meeting, particularly regarding follow-up data that has garnered market attention.
- Improved Financial Performance: Candel reported a Q1 loss of $0.14 per share, better than the expected loss of $0.33, indicating improvements in financial management and operational efficiency, which may boost investor confidence and drive further stock price increases.
See More
Candel Plans to Submit New Drug Application
- Clinical Trial Results: Candel Therapeutics reported that after a median follow-up of 58 months, CAN-2409 demonstrated a 39% improvement in prostate cancer-specific disease-free survival compared to placebo in its pivotal late-stage trial, highlighting the drug's potential in prostate cancer treatment.
- Subgroup Analysis Advantage: In the intermediate-risk subgroup, which comprised 85% of the 745 patients, CAN-2409 achieved a 41% reduction in recurrence risk, along with significant improvements in time to biochemical failure, time to metastasis, and time to next anti-cancer therapy, further solidifying its clinical value.
- FDA Application Plans: Candel intends to submit a Biologics License Application to the FDA in Q4 2026, and if approved, CAN-2409 would be the first new therapy added to standard radiotherapy for localized prostate cancer in over 20 years, marking a significant market opportunity.
- Positive Market Reaction: Following the release of extended follow-up data, Candel's shares rose 3% in after-hours trading, and the stock has increased by 72% over the past 12 months, reflecting strong investor confidence in the drug's prospects.
See More
Candel Therapeutics Reports Earnings, Stock Volatility Observed
- Earnings Beat Expectations: Candel Therapeutics reported a loss of $0.14 per share, significantly better than the consensus estimate of a $0.33 loss, indicating improved financial management that could bolster investor confidence.
- Upcoming Data Presentation: The company is set to present pivotal follow-up data from its Phase 3 prostate cancer trial at the 2026 American Urological Association annual meeting, and positive results could drive stock price increases and attract more investor interest.
- New Lung Cancer Trial: Candel plans to initiate a Phase 3 trial for lung cancer treatment in June 2026, leveraging promising data from a Phase 2 trial where half of the 46 patients survived over 24 months, showcasing the treatment's potential.
- Bullish Market Sentiment: Investor sentiment on Stocktwits is trending bullish with high message volumes, as some users predict that positive follow-up data could push the stock past $12, currently trading around $9, reflecting market optimism about the company's future.
See More
Candel Therapeutics Q1 Earnings Beat Expectations with Strong Cash Position
- Earnings Surprise: Candel Therapeutics reported a Q1 GAAP EPS of -$0.14, beating market expectations by $0.19, indicating improvements in financial management and increased market confidence.
- Strong Cash Position: As of March 31, 2026, the company holds $194.8 million in cash and cash equivalents, expected to fund its operating plan into Q1 2028, ensuring financial stability for the next two years.
- Commercialization Plans: Candel is preparing for the potential commercial launch of its cancer vaccine aglatimagene in 2027, with current funding supporting these activities, reflecting the company's confidence in future market opportunities.
- Public Offering Activity: Candel Therapeutics has launched a $100 million public stock offering; although shares have declined, this move will further strengthen the company's capital base to support its R&D and marketing efforts.
See More
United Community Banks Acquires Candel Therapeutics for $2.2 Billion
- Acquisition Scale: United Community Banks has agreed to acquire Candel Therapeutics for up to $2.2 billion, with $2 billion paid upfront and an additional $200 million contingent on future milestones, aimed at strengthening its pipeline for immune-related disease treatments.
- Expected Timeline: The deal is anticipated to close between late Q2 and early Q3 of 2026, reflecting UCB's confidence and strategic positioning in the future biologics sector.
- Manageable Financial Impact: UCB stated that the financial impact of the acquisition will be manageable, with its 2026 outlook remaining unchanged, projecting steady revenue and profit growth, indicating a positive outlook for future development.
- Candel's Drug Progress: Candel's main drug, cizutamig, is currently undergoing several Phase 1 clinical trials aimed at helping the immune system target harmful cells, further enhancing UCB's innovative capabilities in the biopharmaceutical field.
See More
Candel Therapeutics Stock Seen as Deeply Undervalued Ahead of Key Trial Data
- Valuation Insights: Cantor Fitzgerald initiated coverage of Candel Therapeutics with an 'Overweight' rating, highlighting a discounted cash flow estimate of around $30 per share, indicating a potential 370% upside that reflects strong market confidence in the stock's future performance.
- Clinical Trial Progress: Candel reported encouraging results from a phase 2a clinical trial of CAN-2409 in non-small cell lung cancer, with 50% of patients still alive at two years after one year of follow-up, demonstrating the therapy's potential in activating the immune system and improving survival rates.
- Strong Market Reaction: Candel's stock drew significant retail interest on Monday, with message volume on Stocktwits surging by approximately 70%, reflecting investor optimism ahead of key trial data releases.
- Future Outlook: Investors are eagerly awaiting extended phase 3 results for CAN-2409 in prostate cancer at the 2026 American Urological Association meeting, as well as updates on other programs like CAN-3110, which will further influence the company's market performance.
See More
Candel Plans to Submit Biologics License Application
- Clinical Trial Success: Candel's Phase 3 trial met its primary endpoint, demonstrating that 745 patients receiving the therapy had longer disease-free survival compared to those on standard care, indicating the efficacy of its prostate cancer treatment and potentially accelerating FDA approval.
- Biologics License Application Plan: The company plans to submit a Biologics License Application (BLA) to the U.S. FDA by Q4 2026, marking a critical step towards market entry for its prostate cancer therapy, which is expected to significantly enhance its position in the biopharmaceutical sector.
- Positive Market Reaction: Candel's shares rose 3% in pre-market trading on Friday, reflecting investor optimism ahead of pivotal data presentation at the American Urological Association Annual Meeting, particularly regarding follow-up data that has garnered market attention.
- Improved Financial Performance: Candel reported a Q1 loss of $0.14 per share, better than the expected loss of $0.33, indicating improvements in financial management and operational efficiency, which may boost investor confidence and drive further stock price increases.
See More
Candel Plans to Submit New Drug Application
- Clinical Trial Results: Candel Therapeutics reported that after a median follow-up of 58 months, CAN-2409 demonstrated a 39% improvement in prostate cancer-specific disease-free survival compared to placebo in its pivotal late-stage trial, highlighting the drug's potential in prostate cancer treatment.
- Subgroup Analysis Advantage: In the intermediate-risk subgroup, which comprised 85% of the 745 patients, CAN-2409 achieved a 41% reduction in recurrence risk, along with significant improvements in time to biochemical failure, time to metastasis, and time to next anti-cancer therapy, further solidifying its clinical value.
- FDA Application Plans: Candel intends to submit a Biologics License Application to the FDA in Q4 2026, and if approved, CAN-2409 would be the first new therapy added to standard radiotherapy for localized prostate cancer in over 20 years, marking a significant market opportunity.
- Positive Market Reaction: Following the release of extended follow-up data, Candel's shares rose 3% in after-hours trading, and the stock has increased by 72% over the past 12 months, reflecting strong investor confidence in the drug's prospects.
See More
Candel Therapeutics Reports Earnings, Stock Volatility Observed
- Earnings Beat Expectations: Candel Therapeutics reported a loss of $0.14 per share, significantly better than the consensus estimate of a $0.33 loss, indicating improved financial management that could bolster investor confidence.
- Upcoming Data Presentation: The company is set to present pivotal follow-up data from its Phase 3 prostate cancer trial at the 2026 American Urological Association annual meeting, and positive results could drive stock price increases and attract more investor interest.
- New Lung Cancer Trial: Candel plans to initiate a Phase 3 trial for lung cancer treatment in June 2026, leveraging promising data from a Phase 2 trial where half of the 46 patients survived over 24 months, showcasing the treatment's potential.
- Bullish Market Sentiment: Investor sentiment on Stocktwits is trending bullish with high message volumes, as some users predict that positive follow-up data could push the stock past $12, currently trading around $9, reflecting market optimism about the company's future.
See More
Candel Therapeutics Q1 Earnings Beat Expectations with Strong Cash Position
- Earnings Surprise: Candel Therapeutics reported a Q1 GAAP EPS of -$0.14, beating market expectations by $0.19, indicating improvements in financial management and increased market confidence.
- Strong Cash Position: As of March 31, 2026, the company holds $194.8 million in cash and cash equivalents, expected to fund its operating plan into Q1 2028, ensuring financial stability for the next two years.
- Commercialization Plans: Candel is preparing for the potential commercial launch of its cancer vaccine aglatimagene in 2027, with current funding supporting these activities, reflecting the company's confidence in future market opportunities.
- Public Offering Activity: Candel Therapeutics has launched a $100 million public stock offering; although shares have declined, this move will further strengthen the company's capital base to support its R&D and marketing efforts.
See More
United Community Banks Acquires Candel Therapeutics for $2.2 Billion
- Acquisition Scale: United Community Banks has agreed to acquire Candel Therapeutics for up to $2.2 billion, with $2 billion paid upfront and an additional $200 million contingent on future milestones, aimed at strengthening its pipeline for immune-related disease treatments.
- Expected Timeline: The deal is anticipated to close between late Q2 and early Q3 of 2026, reflecting UCB's confidence and strategic positioning in the future biologics sector.
- Manageable Financial Impact: UCB stated that the financial impact of the acquisition will be manageable, with its 2026 outlook remaining unchanged, projecting steady revenue and profit growth, indicating a positive outlook for future development.
- Candel's Drug Progress: Candel's main drug, cizutamig, is currently undergoing several Phase 1 clinical trials aimed at helping the immune system target harmful cells, further enhancing UCB's innovative capabilities in the biopharmaceutical field.
See More
Candel Therapeutics Stock Seen as Deeply Undervalued Ahead of Key Trial Data
- Valuation Insights: Cantor Fitzgerald initiated coverage of Candel Therapeutics with an 'Overweight' rating, highlighting a discounted cash flow estimate of around $30 per share, indicating a potential 370% upside that reflects strong market confidence in the stock's future performance.
- Clinical Trial Progress: Candel reported encouraging results from a phase 2a clinical trial of CAN-2409 in non-small cell lung cancer, with 50% of patients still alive at two years after one year of follow-up, demonstrating the therapy's potential in activating the immune system and improving survival rates.
- Strong Market Reaction: Candel's stock drew significant retail interest on Monday, with message volume on Stocktwits surging by approximately 70%, reflecting investor optimism ahead of key trial data releases.
- Future Outlook: Investors are eagerly awaiting extended phase 3 results for CAN-2409 in prostate cancer at the 2026 American Urological Association meeting, as well as updates on other programs like CAN-3110, which will further influence the company's market performance.
See More
